The Economic Impact of Medicare Part D on Congestive Heart Failure – See more at:

AJMC: May 14, 2013

Congestive heart failure (CHF) is the most common reason for hospitalization among the elderly, accounting for one-fifth of all admissions.1 Consequently, beneficiaries with CHF are among the most costly to Medicare; they represent 14% of the population, but account for 43% of Medicare Part A and B spending.2 More than 3.5 million Part D enrollees were diagnosed with CHF in 2010.3

Extensive evidence demonstrates that medications can be used to effectively treat and manage CHF by slowing disease progression, allaying symptoms, and reducing use of medical services such as hospitalizations.4-7 However, adherence to CHF medications remains suboptimal, suggesting the potential for improvements in outcomes and medical cost savings. For example, Roebuck and colleagues found that patients with CHF who were adherent to medications experienced 5.7 fewer hospital days and $8881 in reduced medical expenditure annually compared with patients who were not adherent.6 Another study found that each 10% increase in the use of CHF medications was associated with reductions in 3-year Medicare Part A and B expenditures of $510 to $923 (2006 dollars).8   Read more